• info@proteinlounge.com

Animations

Animations

Anti-PD-1 PD-L1 therapy of human cancer

Description

PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth.

Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.

Browse Other Animations

Fluorescence-Linked Immunosorbent Assay
Fluorescent labels provide high levels of sensitivity for a wide range of analytical procedures.[...]
Breast Cancer Pathogenesis
Breast cancer is the most common cancer worldwide, and the second leading cause of cancer[...]
Malaria
Malaria is a vector-borne infectious disease caused by a protozoan parasite of the genus[...]
Allergy
Allergies are abnormal immune responses to allergens like pollen grains, dust, moulds and[...]
logo

 

9853 Pacific Heights Blvd.
Suite D., San Diego, CA 92121, USA

Tel: 858-224-2869
Fax: 858-205-1192
info@proteinlounge.com

Institutional License

Need our databases and tools to be availed by your whole university or institute? We recommend signing up for our Site License.

To set up a license, please contact: info@proteinlounge.com

Copyright © Protein Lounge Inc.
   Terms & Conditions